Abion (203400) Stock Overview

Abion Inc. engages in the development of chemical and biological drugs, and vaccines in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a drug candidate for lung and stomach cancer; ABN501, a biomarker for ovarian cancer; and ABN201, a fusion protein to target cancer cells. It also develops ABN101, an interferon-beta based biological drug for the treatment of autoimmune diseases in the central nervous system. In addition, the company is developing medical countermeasure vaccines, such as ABN701, a vaccine that protects against infection from staphylococcal enterotoxin B; and ABN601, a drug for the protection of immune system from acute radiation syndrome. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.